This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the recent data on Carvykti and the state of CAR-T therapies in use for multiple myeloma.
Ticker(s): JNJWho's the expert?
Institution: UCSF
- Clinical Professor of Medicine (Hematology/Oncology), Director of the Hematologic Malignancies Research Site Committee, Co-Director of the Myeloma Program & Co-Lead for the Hematologic Malignancies Research Program in the Helen Diller Family Comprehensive Cancer Center at UCSF.
- Currently manages 40 patients a week with multiple myeloma.
- PI on over 25 clinical trials; research interests are the development and evaluation of novel therapeutics for multiple myeloma including antibody-drug conjugate trials and cellular therapy trials in relapsed MM.
Interview GoalThe call will discuss the recent data releases on Carvykti and other CAR-T therapies that are currently being studied and used for the treatment of Multiple Myeloma.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
